Vascular damage causes platelets to adhere to exposed subendothelial collagen. The adherent platelets release ADP which makes passing platelets """"""""stricky"""""""" so that an aggregate is formed. Such aggregates may be either beneficial or harmful because they can promote both hemostasis and thrombosis. (Although thrombin is also involved in hemostasis and thrombosis, we will not study its role or the mechanisms of platelet secretion.) We will elucidate the mechanisms of platelet aggregation using in vitro biochemical and physiological methods. Stimulation of normal platelets with ADP causes the appearance of fibrinogen receptors and aggregation if sufficient fibrinogen is bound. Abnormal platelets which cannot bind fibrinogen also cannot aggregate. We would like to determine how the fibrinogen receptor is induced, to which membrane components the fibrinogen binds, the distribution of bound fibrinogen on platelets in aggregates and of fibrinogen receptors on adherent platelets, the role of membrane fluidity in aggregation, the relationship of aggregability and fibrinogen binding to platelet charge (electrophoretic mobility), and the possible loss of radioactive surface labels from platelets when they aggregate. In addition to normal platelets stimulated with ADP, we will use platelets incubated with chymotrypsin which aggredate on addition of fibrinogen without ADP, and platelets incubated with EDTA which retain many functions but cannot aggregate even after addition of ADP, fibrinogen and calcium.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL027752-05
Application #
3339291
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1981-12-01
Project End
1987-11-30
Budget Start
1985-12-01
Budget End
1987-11-30
Support Year
5
Fiscal Year
1986
Total Cost
Indirect Cost
Name
New York University
Department
Type
Schools of Medicine
DUNS #
004514360
City
New York
State
NY
Country
United States
Zip Code
10012
McPherson, J; Zucker, M B; Mauss, E A et al. (1991) The effect of agonists and antagonists of platelet aggregation on von Willebrand factor-mediated platelet agglutination. Thromb Haemost 65:573-7
Zucker, M B; Katz, I R (1991) Platelet factor 4: production, structure, and physiologic and immunologic action. Proc Soc Exp Biol Med 198:693-702
Puszkin, E G; Mauss, E A; Zucker, M B (1990) Assembly and GPIIIa content of cytoskeletal core in platelets agglutinated with bovine von Willebrand factor. Blood 76:1572-9
Zucker, M B; Puszkin, E G; Sussman, I I et al. (1990) Inhibition of von Willebrand factor-induced platelet agglutination by ADP does not result from reduced binding of total von Willebrand factor or its larger multimers. J Lab Clin Med 116:305-14
Zucker, M B; Katz, I R; Thorbecke, G J et al. (1989) Immunoregulatory activity of peptides related to platelet factor 4. Proc Natl Acad Sci U S A 86:7571-4
Puszkin, E G; Mauss, E A; Milot, D C et al. (1989) Effect of the thiol group inhibitor monobromobimane and other inhibitors on the composition of the platelet cytoskeletal core and its association with glycoprotein IIIa. J Cell Biochem 39:339-54
Zucker, M B; Mauss, E A (1988) Erythrocyte aggregation in iohexol and other nonionic media. Invest Radiol 23 Suppl 2:S340-5
Yin, J Z; Zucker, M B; Clarke, D et al. (1988) Prevention by a platelet-derived factor (platelet factor 4) of induction of low dose tolerance to pneumococcal polysaccharides. Cell Immunol 115:221-7
Barone, A D; Ghrayeb, J; Hammerling, U et al. (1988) The expression in Escherichia coli of recombinant human platelet factor 4, a protein with immunoregulatory activity. J Biol Chem 263:8710-5
Zucker, M B; Brownlea, S; McPherson, J (1987) Insights into the mechanism of platelet retention in glass bead columns. Ann N Y Acad Sci 516:398-406

Showing the most recent 10 out of 16 publications